Raras
Buscar doenças, sintomas, genes...
Lúpus eritematoso sistêmico
ORPHA:536CID-10 · M32.0CID-11 · 4A40.0OMIM 152700PCDT · SUSDOENÇA RARA

Doença autoimune de múltiplos órgãos tipicamente associada a vasculopatia e produção de autoanticorpos. A maioria dos pacientes apresenta anticorpos antinucleares (ANA). A presença de anticorpos anti-dsDNA ou anti-Smith é altamente específica.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Doença autoimune de múltiplos órgãos tipicamente associada a vasculopatia e produção de autoanticorpos. A maioria dos pacientes apresenta anticorpos antinucleares (ANA). A presença de anticorpos anti-dsDNA ou anti-Smith é altamente específica.

Pesquisas ativas
40 ensaios
1146 total registrados no ClinicalTrials.gov
Publicações científicas
68.083 artigos
Último publicado: 2026 Apr 17

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-5 / 10 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
47.0
France
Início
Adolescent
+ adult, childhood, infancy
🏥
SUS: Cobertura parcialScore: 50%
PCDT disponível1 medicamentos CEAFCID-10: M32.0
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🩸
Sangue
14 sintomas
🫃
Digestivo
11 sintomas
🧬
Pele e cabelo
10 sintomas
❤️
Coração
10 sintomas
🫘
Rins
9 sintomas
🧠
Neurológico
8 sintomas

+ 71 sintomas em outras categorias

Características mais comuns

90%prev.
Fadiga
Muito frequente (99-80%)
90%prev.
Positividade do anticorpo antinuclear
Muito frequente (99-80%)
90%prev.
Mal-estar
Muito frequente (99-80%)
90%prev.
Perda de peso
Muito frequente (99-80%)
90%prev.
Febre
Muito frequente (99-80%)
90%prev.
Proteinúria
Muito frequente (99-80%)
155sintomas
Muito frequente (7)
Frequente (18)
Ocasional (19)
Muito raro (2)
Sem dados (109)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 155 características clínicas mais associadas, ordenadas por frequência.

FadigaFatigue
Muito frequente (99-80%)90%
Positividade do anticorpo antinuclearAntinuclear antibody positivity
Muito frequente (99-80%)90%
Mal-estarMalaise
Muito frequente (99-80%)90%
Perda de pesoWeight loss
Muito frequente (99-80%)90%
FebreFever
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico68.083PubMed
Últimos 10 anos200publicações
Pico2026199 papers
Linha do tempo
2026Hoje · 2026🧪 1986Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

36 genes identificados com associação a esta condição. Padrão de herança: Not applicable.

ITGAMIntegrin alpha-MMajor susceptibility factor inTolerante
FUNÇÃO

Integrin ITGAM/ITGB2 is implicated in various adhesive interactions of monocytes, macrophages and granulocytes as well as in mediating the uptake of complement-coated particles and pathogens (PubMed:20008295, PubMed:9558116). It is identical with CR-3, the receptor for the iC3b fragment of the third complement component. It probably recognizes the R-G-D peptide in C3b. Integrin ITGAM/ITGB2 is also a receptor for fibrinogen and factor X. It recognizes P1 and P2 peptides of fibrinogen gamma chain.

LOCALIZAÇÃO

Cell membraneMembrane raft

VIAS BIOLÓGICAS (1)
Neutrophil degranulation
MECANISMO DE DOENÇA

Systemic lupus erythematosus 6

A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
148.8 TPM
Baço
47.9 TPM
Pulmão
30.6 TPM
Adipose Visceral Omentum
15.1 TPM
Tecido adiposo
13.0 TPM
OUTRAS DOENÇAS (1)
systemic lupus erythematosus
HGNC:6149UniProt:P11215
FCGR2ALow affinity immunoglobulin gamma Fc region receptor II-aCandidate gene tested inTolerante
FUNÇÃO

Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
FCGR activationNeutrophil degranulation
EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
342.9 TPM
Pulmão
57.9 TPM
Baço
57.1 TPM
Aorta
30.2 TPM
Adipose Visceral Omentum
29.2 TPM
OUTRAS DOENÇAS (3)
malaria, susceptibility tosystemic lupus erythematosuscystic fibrosis
HGNC:HGNC:3616UniProt:P12318
C1RComplement C1r subcomponentCandidate gene tested inTolerante
FUNÇÃO

Serine protease component of the complement C1 complex, a multiprotein complex that initiates the classical pathway of the complement system, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:17996945, PubMed:19473974, PubMed:29449492). C1R catalyzes the first enzymatic step in the classical complement pathway: it is activated by the C1Q subcomplex of the C1 complex, which associates with IgG or IgM immun

LOCALIZAÇÃO

SecretedCell surface

VIAS BIOLÓGICAS (3)
Initial triggering of complementClassical antibody-mediated complement activationRegulation of Complement cascade
MECANISMO DE DOENÇA

Ehlers-Danlos syndrome, periodontal type, 1

A form of Ehlers-Danlos syndrome, a connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. EDSPD1 is characterized by the association of typical features of Ehlers-Danlos syndrome with gingival recession and severe early-onset periodontal disease, leading to premature loss of permanent teeth. EDSPD1 inheritance is autosomal dominant.

OUTRAS DOENÇAS (4)
Ehlers-Danlos syndrome, periodontal type 1immunodeficiency due to a classical component pathway complement deficiencyEhlers-Danlos syndrome, periodontitis typeautosomal systemic lupus erythematosus type 16
HGNC:1246UniProt:P00736
C1QAComplement C1q subcomponent subunit ACandidate gene tested inModerado
FUNÇÃO

Core component of the complement C1 complex, a multiprotein complex that initiates the classical pathway of the complement system, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:12847249, PubMed:19006321, PubMed:24626930, PubMed:29449492, PubMed:3258649, PubMed:34155115, PubMed:6249812, PubMed:6776418). The classical complement pathway is initiated by the C1Q subcomplex of the C1 complex, which specifi

LOCALIZAÇÃO

SecretedCell surface

VIAS BIOLÓGICAS (4)
Initial triggering of complementClassical antibody-mediated complement activationRegulation of Complement cascadeDengue virus activates/modulates innate and adaptive immune responses
MECANISMO DE DOENÇA

C1q deficiency 1

An autosomal recessive disorder caused by impaired activation of the complement classical pathway. It generally leads to severe immune complex disease characterized by recurrent skin lesions, chronic infections, an increased risk of systemic lupus erythematosus, and glomerulonephritis.

OUTRAS DOENÇAS (3)
C1Q deficiency 1autosomal systemic lupus erythematosus type 16immunodeficiency due to a classical component pathway complement deficiency
HGNC:1241UniProt:P02745
SAT1Sulfate anion transporter 1Candidate gene tested inAltamente restrito
FUNÇÃO

Sodium-independent sulfate anion transporter (PubMed:12713736, PubMed:27125215). Can transport other anions including bicarbonate, thiosulfate and oxalate by mediating sulfate-thiosulfate, sulfate-hydrogencarbonate and sulfate-oxalate anion exchange (PubMed:12713736, PubMed:27125215). Mediates oxalate-hydrogencarbonate anion exchange (By similarity)

LOCALIZAÇÃO

Cell membraneBasolateral cell membrane

VIAS BIOLÓGICAS (1)
Interconversion of polyamines
MECANISMO DE DOENÇA

Nephrolithiasis, calcium oxalate, 1

A form of nephrolithiasis, a condition in which urinary supersaturation leads to stone formation in the urinary system. Patients manifest acute renal colic with severe pain originating in the flank. Patients with small, non-obstructing stones or those with staghorn calculi may be asymptomatic. The majority of renal calculi contain calcium. CAON1 is characterized by calcium oxalate kidney stones.

EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
1175.2 TPM
Baço
817.9 TPM
Sangue
793.1 TPM
Adipose Visceral Omentum
767.7 TPM
Tireoide
643.7 TPM
OUTRAS DOENÇAS (2)
pediatric systemic lupus erythematosuskeratosis follicularis spinulosa decalvans
HGNC:10540UniProt:Q9H2B4
DNASE1L3Deoxyribonuclease gammaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Has DNA hydrolytic activity. Is capable of both single- and double-stranded DNA cleavage, producing DNA fragments with 3'-OH ends (By similarity). Can cleave chromatin to nucleosomal units and cleaves nucleosomal and liposome-coated DNA (PubMed:10807908, PubMed:14646506, PubMed:27293190, PubMed:9070308, PubMed:9714828). Acts in internucleosomal DNA fragmentation (INDF) during apoptosis and necrosis (PubMed:23229555, PubMed:24312463). The role in apoptosis includes myogenic and neuronal different

LOCALIZAÇÃO

NucleusEndoplasmic reticulumSecreted

MECANISMO DE DOENÇA

Systemic lupus erythematosus 16

A rare autosomal recessive form of systemic lupus erythematosus with childhood onset, characterized by high frequency of anti-neutrophil cytoplasmic antibodies and lupus nephritis. Systemic lupus erythematosus is a chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

EXPRESSÃO TECIDUAL(Ubíquo)
Baço
106.0 TPM
Rim - Medula
29.1 TPM
Glândula adrenal
24.3 TPM
Fígado
21.1 TPM
Pituitária
17.7 TPM
OUTRAS DOENÇAS (2)
autosomal systemic lupus erythematosus type 16hypocomplementemic urticarial vasculitis
HGNC:2959UniProt:Q13609
PLD45'-3' exonuclease PLD4Disease-causing germline mutation(s) inTolerante
FUNÇÃO

5'->3' exonuclease that hydrolyzes the phosphodiester bond of single-stranded DNA (ssDNA) and RNA molecules to form nucleoside 3'-monophosphates and 5'-end 5'-hydroxy deoxyribonucleotide/ribonucleotide fragments (PubMed:30111894, PubMed:34620855, PubMed:38537643, PubMed:39423811). Partially redundant with PLD3, can cleave all four nucleotides displaying higher efficiency for ssDNA and RNA fragments initiated with uridine and guanosine residues and lower efficiency for cytidine-initiated substrat

LOCALIZAÇÃO

Endoplasmic reticulum membraneGolgi apparatus, trans-Golgi network membraneNucleusEarly endosomeCytoplasmic vesicle, phagosomeLysosome

VIAS BIOLÓGICAS (1)
Role of phospholipids in phagocytosis
EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Spinal cord cervical c-1
5.4 TPM
Baço
4.4 TPM
Cerebelo
3.8 TPM
Linfócitos
3.7 TPM
Cérebro - Hemisfério cerebelar
3.0 TPM
OUTRAS DOENÇAS (1)
systemic lupus erythematosus 18
HGNC:HGNC:23792UniProt:Q96BZ4
UBE2L3Ubiquitin-conjugating enzyme E2 L3Major susceptibility factor inAltamente restrito
FUNÇÃO

Ubiquitin-conjugating enzyme E2 that specifically acts with HECT-type and RBR family E3 ubiquitin-protein ligases. Does not function with most RING-containing E3 ubiquitin-protein ligases because it lacks intrinsic E3-independent reactivity with lysine; in contrast, it has activity with the RBR family E3 enzymes, such as PRKN, RNF31 and ARIH1, that function like RING-HECT hybrids. Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. Mediates ubiquitinati

LOCALIZAÇÃO

NucleusCytoplasm

VIAS BIOLÓGICAS (4)
PINK1-PRKN Mediated MitophagyAntigen processing: Ubiquitination & Proteasome degradationE3 ubiquitin ligases ubiquitinate target proteinsSynthesis of active ubiquitin: roles of E1 and E2 enzymes
EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
97.1 TPM
Artéria tibial
87.2 TPM
Cérebro - Hemisfério cerebelar
85.5 TPM
Cerebelo
82.4 TPM
Linfócitos
80.9 TPM
OUTRAS DOENÇAS (1)
systemic lupus erythematosus
HGNC:12488UniProt:P68036
TNFAIP3Tumor necrosis factor alpha-induced protein 3Major susceptibility factor inAltamente restrito
FUNÇÃO

Ubiquitin-editing enzyme that contains both ubiquitin ligase and deubiquitinase activities. Involved in immune and inflammatory responses signaled by cytokines, such as TNF and IL-1 beta, or pathogens via Toll-like receptors (TLRs) through terminating NF-kappa-B activity. Essential component of a ubiquitin-editing protein complex, comprising also RNF11, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signaling pathways. In cooperation with TAX1BP1 promotes disassembly of E2-E

LOCALIZAÇÃO

CytoplasmNucleusLysosome

VIAS BIOLÓGICAS (6)
Ovarian tumor domain proteasesNOD1/2 Signaling PathwayNegative regulators of DDX58/IFIH1 signalingRegulation of TNFR1 signalingTNFR1-induced proapoptotic signaling
MECANISMO DE DOENÇA

Autoinflammatory syndrome, familial, Behcet-like 1

An autosomal dominant, autoinflammatory disorder with early onset, characterized by ulceration of mucosal surfaces, particularly in the oral and genital areas. Additional variable features include skin rash, uveitis, and polyarthritis.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
245.4 TPM
Ovário
109.7 TPM
Pulmão
74.4 TPM
Adipose Visceral Omentum
63.8 TPM
Skin Not Sun Exposed Suprapubic
58.3 TPM
OUTRAS DOENÇAS (2)
autoinflammatory syndrome, familial, Behcet-like 1systemic lupus erythematosus
HGNC:11896UniProt:P21580
SPP1Sphingosine-1-phosphate phosphatase 1Major susceptibility factor inTolerante
FUNÇÃO

Specifically dephosphorylates sphingosine 1-phosphate (S1P), dihydro-S1P, and phyto-S1P. Does not act on ceramide 1-phosphate, lysophosphatidic acid or phosphatidic acid (PubMed:16782891). Sphingosine-1-phosphate phosphatase activity is needed for efficient recycling of sphingosine into the sphingolipid synthesis pathway (PubMed:11756451, PubMed:12815058, PubMed:16782891). Regulates the intracellular levels of the bioactive sphingolipid metabolite S1P that regulates diverse biological processes

LOCALIZAÇÃO

Endoplasmic reticulum membraneCell membrane

VIAS BIOLÓGICAS (2)
Post-translational protein phosphorylationRegulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Rim - Medula
3688.8 TPM
Brain Spinal cord cervical c-1
1888.9 TPM
Rim - Córtex
1847.0 TPM
Substância negra
471.4 TPM
Hipocampo
218.7 TPM
OUTRAS DOENÇAS (2)
pediatric systemic lupus erythematosussystemic lupus erythematosus
HGNC:11255UniProt:Q9BX95
TNFSF4Tumor necrosis factor ligand superfamily member 4Major susceptibility factor inModerado
FUNÇÃO

Cytokine that binds to TNFRSF4. Co-stimulates T-cell proliferation and cytokine production

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (1)
TNFs bind their physiological receptors
MECANISMO DE DOENÇA

Systemic lupus erythematosus

A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
9.8 TPM
Fibroblastos
6.5 TPM
Testículo
5.3 TPM
Esôfago - Junção
4.2 TPM
Cérebro - Hemisfério cerebelar
3.7 TPM
OUTRAS DOENÇAS (3)
narcolepsy-cataplexy syndromesystemic lupus erythematosusmyocardial infarction, susceptibility to
HGNC:11934UniProt:P23510
TREX1Three-prime repair exonuclease 1Major susceptibility factor inTolerante
FUNÇÃO

Major cellular 3'-to-5' DNA exonuclease which digests single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA) with mismatched 3' termini (PubMed:10391904, PubMed:10393201, PubMed:17293595). Prevents cell-intrinsic initiation of autoimmunity (PubMed:10391904, PubMed:10393201, PubMed:17293595). Acts by metabolizing DNA fragments from endogenous retroelements, including L1, LTR and SINE elements (PubMed:10391904, PubMed:10393201, PubMed:17293595). Plays a key role in degradation of DNA fragment

LOCALIZAÇÃO

NucleusCytoplasm, cytosolEndoplasmic reticulum membrane

VIAS BIOLÓGICAS (2)
IRF3-mediated induction of type I IFNRegulation by TREX1
MECANISMO DE DOENÇA

Aicardi-Goutieres syndrome 1

A form of Aicardi-Goutieres syndrome, a genetically heterogeneous disease characterized by cerebral atrophy, leukoencephalopathy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, increased CSF alpha-interferon, and negative serologic investigations for common prenatal infection. Clinical features as thrombocytopenia, hepatosplenomegaly and elevated hepatic transaminases along with intermittent fever may erroneously suggest an infective process. Severe neurological dysfunctions manifest in infancy as progressive microcephaly, spasticity, dystonic posturing and profound psychomotor retardation. Death often occurs in early childhood.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
80.6 TPM
Baço
45.2 TPM
Skin Sun Exposed Lower leg
42.6 TPM
Skin Not Sun Exposed Suprapubic
42.3 TPM
Pituitária
42.0 TPM
OUTRAS DOENÇAS (6)
retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestationschilblain lupus 1Aicardi-Goutieres syndrome 1Aicardi-Goutieres syndrome
HGNC:12269UniProt:Q9NSU2
TNIP1TNFAIP3-interacting protein 1Major susceptibility factor inAltamente restrito
FUNÇÃO

Inhibits NF-kappa-B activation and TNF-induced NF-kappa-B-dependent gene expression by regulating TAX1BP1 and A20/TNFAIP3-mediated deubiquitination of IKBKG; proposed to link A20/TNFAIP3 to ubiquitinated IKBKG (PubMed:21885437). Involved in regulation of EGF-induced ERK1/ERK2 signaling pathway; blocks MAPK3/MAPK1 nuclear translocation and MAPK1-dependent transcription. Increases cell surface CD4(T4) antigen expression. Involved in the anti-inflammatory response of macrophages and positively regu

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
Ovarian tumor domain proteases
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
315.5 TPM
Sangue
151.1 TPM
Tecido adiposo
122.0 TPM
Baço
119.2 TPM
Pulmão
109.3 TPM
OUTRAS DOENÇAS (1)
systemic lupus erythematosus
HGNC:16903UniProt:Q15025
TLR7Toll-like receptor 7Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Endosomal receptor that plays a key role in innate and adaptive immunity (PubMed:14976261, PubMed:32433612). Controls host immune response against pathogens through recognition of uridine-containing single strand RNAs (ssRNAs) of viral origin or guanosine analogs (PubMed:12738885, PubMed:27742543, PubMed:31608988, PubMed:32706371, PubMed:35477763). Upon binding to agonists, undergoes dimerization that brings TIR domains from the two molecules into direct contact, leading to the recruitment of TI

LOCALIZAÇÃO

Endoplasmic reticulum membraneEndosomeLysosomeCytoplasmic vesicle, phagosome

VIAS BIOLÓGICAS (1)
Trafficking and processing of endosomal TLR
MECANISMO DE DOENÇA

Immunodeficiency 74, COVID19-related, X-linked

An X-linked recessive immunologic disorder characterized by impaired type I and type II interferon responses due to defective TLR7 signaling. Individuals with TLR7 deficiency develop severe respiratory insufficiency in response to infection with SARS-CoV-2 coronavirus. Death from respiratory failure may occur.

EXPRESSÃO TECIDUAL(Tecido-específico)
Linfócitos
40.5 TPM
Baço
2.3 TPM
Brain Spinal cord cervical c-1
2.1 TPM
Intestino delgado
1.3 TPM
Substância negra
1.2 TPM
OUTRAS DOENÇAS (3)
systemic lupus erythematosus 17immunodeficiency 74, COVID-19-related, X-linkedsystemic lupus erythematosus
HGNC:15631UniProt:Q9NYK1
STAT4Signal transducer and activator of transcription 4Major susceptibility factor inAltamente restrito
FUNÇÃO

Transcriptional regulator mainly expressed in hematopoietic cells that plays a critical role in cellular growth, differentiation and immune response (PubMed:10961885, PubMed:37256972, PubMed:8943379). Plays a key role in the differentiation of T-helper 1 cells and the production of interferon-gamma (PubMed:12213961, PubMed:35614130). Also participates in multiple neutrophil functions including chemotaxis and production of the neutrophil extracellular traps (By similarity). After IL12 binding to

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (5)
Interleukin-20 family signalingInterleukin-21 signalingInterleukin-12 signalingInterleukin-35 SignallingInterleukin-23 signaling
MECANISMO DE DOENÇA

Systemic lupus erythematosus 11

A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
34.7 TPM
Pituitária
24.0 TPM
Brain Frontal Cortex BA9
17.3 TPM
Baço
16.7 TPM
Córtex cerebral
15.3 TPM
OUTRAS DOENÇAS (7)
disabling pansclerotic morphea of childhoodpediatric systemic lupus erythematosusoligoarticular juvenile idiopathic arthritissystemic lupus erythematosus
HGNC:11365UniProt:Q14765
PTPN22Tyrosine-protein phosphatase non-receptor type 22Major susceptibility factor inTolerante
FUNÇÃO

Acts as a negative regulator of T-cell receptor (TCR) signaling by direct dephosphorylation of the Src family kinases LCK and FYN, ITAMs of the TCRz/CD3 complex, as well as ZAP70, VAV, VCP and other key signaling molecules (PubMed:16461343, PubMed:18056643). Associates with and probably dephosphorylates CBL. Dephosphorylates LCK at its activating 'Tyr-394' residue (PubMed:21719704). Dephosphorylates ZAP70 at its activating 'Tyr-493' residue (PubMed:16461343). Dephosphorylates the immune system a

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (2)
Phosphorylation of CD3 and TCR zeta chainsTranslocation of ZAP-70 to Immunological synapse
MECANISMO DE DOENÇA

Systemic lupus erythematosus

A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

EXPRESSÃO TECIDUAL(Tecido-específico)
Linfócitos
50.6 TPM
Baço
13.9 TPM
Sangue
12.7 TPM
Intestino delgado
9.6 TPM
Pulmão
8.7 TPM
OUTRAS DOENÇAS (6)
systemic lupus erythematosusVogt-Koyanagi-Harada diseaseoligoarticular juvenile idiopathic arthritisrheumatoid factor-negative juvenile idiopathic arthritis
HGNC:9652UniProt:Q9Y2R2
PXKPX domain-containing protein kinase-like proteinMajor susceptibility factor inRestrito
FUNÇÃO

Binds to and modulates brain Na,K-ATPase subunits ATP1B1 and ATP1B3 and may thereby participate in the regulation of electrical excitability and synaptic transmission. May not display kinase activity

LOCALIZAÇÃO

CytoplasmCell membrane

VIAS BIOLÓGICAS (1)
Degradation of cysteine and homocysteine
EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
72.1 TPM
Cervix Ectocervix
58.3 TPM
Tireoide
44.0 TPM
Cervix Endocervix
42.1 TPM
Cérebro - Hemisfério cerebelar
39.8 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (1)
systemic lupus erythematosus
HGNC:23326UniProt:Q7Z7A4
KIAA0319LDyslexia-associated protein KIAA0319-like proteinMajor susceptibility factor inRestrito
FUNÇÃO

Possible role in axon guidance through interaction with RTN4R (Microbial infection) Acts as a receptor for adeno-associated virus and is involved in adeno-associated virus infection through endocytosis system

LOCALIZAÇÃO

Cytoplasmic granule membraneGolgi apparatus membraneGolgi apparatus, trans-Golgi network membraneCell membrane

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
34.9 TPM
Tireoide
34.7 TPM
Nervo tibial
31.5 TPM
Cérebro - Hemisfério cerebelar
30.8 TPM
Cerebelo
29.9 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (2)
systemic lupus erythematosuslimited cutaneous systemic sclerosis
HGNC:30071UniProt:Q8IZA0
MECP2Methyl-CpG-binding protein 2Major susceptibility factor inAltamente restrito
FUNÇÃO

Chromosomal protein that binds to methylated DNA. It can bind specifically to a single methyl-CpG pair. It is not influenced by sequences flanking the methyl-CpGs. Mediates transcriptional repression through interaction with histone deacetylase and the corepressor SIN3A. Binds both 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC)-containing DNA, with a preference for 5-methylcytosine (5mC)

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (7)
MECP2 regulates transcription of neuronal ligandsRegulation of MECP2 expression and activityMECP2 regulates neuronal receptors and channelsMECP2 regulates transcription factorsTranscriptional Regulation by MECP2
MECANISMO DE DOENÇA

Angelman syndrome

A neurodevelopmental disorder characterized by severe motor and intellectual retardation, ataxia, frequent jerky limb movements and flapping of the arms and hands, hypotonia, seizures, absence of speech, frequent smiling and episodes of paroxysmal laughter, open-mouthed expression revealing the tongue.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
38.8 TPM
Cerebelo
34.5 TPM
Útero
28.9 TPM
Artéria tibial
28.1 TPM
Fallopian Tube
27.9 TPM
OUTRAS DOENÇAS (8)
syndromic X-linked intellectual disability Lubs typeRett syndromeX-linked intellectual disability-psychosis-macroorchidism syndromesevere neonatal-onset encephalopathy with microcephaly
HGNC:6990UniProt:P51608
ETS1Protein C-ets-1Major susceptibility factor inAltamente restrito
FUNÇÃO

Transcription factor (PubMed:10698492, PubMed:11909962). Directly controls the expression of cytokine and chemokine genes in a wide variety of different cellular contexts (PubMed:20378371). May control the differentiation, survival and proliferation of lymphoid cells (PubMed:20378371). May also regulate angiogenesis through regulation of expression of genes controlling endothelial cell migration and invasion (PubMed:15247905, PubMed:15592518) Acts as a dominant-negative for isoform c-ETS-1A

LOCALIZAÇÃO

NucleusCytoplasm

VIAS BIOLÓGICAS (1)
Oncogene Induced Senescence
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
124.4 TPM
Baço
112.3 TPM
Adipose Visceral Omentum
97.2 TPM
Tecido adiposo
94.2 TPM
Pulmão
93.5 TPM
OUTRAS DOENÇAS (1)
systemic lupus erythematosus
HGNC:3488UniProt:P14921
IRAK1Interleukin-1 receptor-associated kinase 1Major susceptibility factor inAltamente restrito
FUNÇÃO

Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. Involved in Toll-like receptor (TLR) and IL-1R signaling pathways. Is rapidly recruited by MYD88 to the receptor-signaling complex upon TLR activation. Association with MYD88 leads to IRAK1 phosphorylation by IRAK4 and subsequent autophosphorylation and kinase activation. Phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and PELI3) to promote pellino-mediate

LOCALIZAÇÃO

CytoplasmNucleusLipid droplet

VIAS BIOLÓGICAS (8)
PI5P, PP2A and IER3 Regulate PI3K/AKT SignalingPIP3 activates AKT signalingMyD88:MAL(TIRAP) cascade initiated on plasma membraneMyD88 cascade initiated on plasma membraneMyD88 dependent cascade initiated on endosome
EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
134.7 TPM
Baço
95.4 TPM
Pulmão
79.8 TPM
Esôfago - Mucosa
76.8 TPM
Linfócitos
75.7 TPM
OUTRAS DOENÇAS (2)
systemic lupus erythematosuspediatric systemic lupus erythematosus
HGNC:6112UniProt:P51617
BANK1B-cell scaffold protein with ankyrin repeatsMajor susceptibility factor inTolerante
FUNÇÃO

Involved in B-cell receptor (BCR)-induced Ca(2+) mobilization from intracellular stores. Promotes Lyn-mediated phosphorylation of IP3 receptors 1 and 2

LOCALIZAÇÃO

MECANISMO DE DOENÇA

Systemic lupus erythematosus

A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

OUTRAS DOENÇAS (1)
systemic lupus erythematosus
HGNC:18233UniProt:Q8NDB2
JAZF1Juxtaposed with another zinc finger protein 1Major susceptibility factor inAltamente restrito
FUNÇÃO

Acts as a transcriptional corepressor of orphan nuclear receptor NR2C2 (PubMed:15302918). Inhibits expression of the gluconeogenesis enzyme PCK2 through inhibition of NR2C2 activity (By similarity). Also involved in transcriptional activation of NAMPT by promoting expression of PPARA and PPARD (By similarity). Plays a role in lipid metabolism by suppressing lipogenesis, increasing lipolysis and decreasing lipid accumulation in adipose tissue (By similarity). Plays a role in glucose homeostasis b

LOCALIZAÇÃO

Nucleus

EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Ectocervix
87.7 TPM
Útero
57.6 TPM
Cervix Endocervix
57.4 TPM
Artéria tibial
50.2 TPM
Cérebro - Hemisfério cerebelar
48.3 TPM
OUTRAS DOENÇAS (2)
systemic lupus erythematosusendometrioid stromal sarcoma
HGNC:28917UniProt:Q86VZ6
DNASE1Deoxyribonuclease-1Major susceptibility factor inTolerante
FUNÇÃO

Serum endocuclease secreted into body fluids by a wide variety of exocrine and endocrine organs (PubMed:11241278, PubMed:2251263, PubMed:2277032). Expressed by non-hematopoietic tissues and preferentially cleaves protein-free DNA (By similarity). Among other functions, seems to be involved in cell death by apoptosis (PubMed:11241278). Binds specifically to G-actin and blocks actin polymerization (By similarity). Together with DNASE1L3, plays a key role in degrading neutrophil extracellular traps

LOCALIZAÇÃO

SecretedZymogen granuleNucleus envelope

VIAS BIOLÓGICAS (1)
Neutrophil degranulation
MECANISMO DE DOENÇA

Systemic lupus erythematosus

A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

VIAS REACTOME (2)
EXPRESSÃO TECIDUAL(Ubíquo)
Rim - Medula
15.3 TPM
Intestino delgado
14.8 TPM
Pituitária
14.7 TPM
Cerebelo
13.8 TPM
Cérebro - Hemisfério cerebelar
13.8 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (2)
systemic lupus erythematosusautosomal systemic lupus erythematosus type 16
HGNC:2956UniProt:P24855
CTLA4Cytotoxic T-lymphocyte protein 4Major susceptibility factor inAltamente restrito
FUNÇÃO

Inhibitory receptor acting as a major negative regulator of T-cell responses (PubMed:11279501, PubMed:11279502, PubMed:16551244, PubMed:1714933, PubMed:18641304, PubMed:28484017). Acts as a decoy receptor: the affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28 (PubMed:11279501, PubMed:11279502, PubMed:16551244, PubMed:1714933, PubMed:28484017)

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (3)
Co-stimulation by CD28Co-inhibition by CTLA4RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)
MECANISMO DE DOENÇA

Systemic lupus erythematosus

A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

EXPRESSÃO TECIDUAL(Tecido-específico)
Baço
5.8 TPM
Intestino delgado
4.9 TPM
Pulmão
4.3 TPM
Testículo
2.5 TPM
Sangue
1.8 TPM
OUTRAS DOENÇAS (6)
autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiencysystemic lupus erythematosusgranulomatosis with polyangiitismycosis fungoides
HGNC:2505UniProt:P16410
C4BComplement C4-BMajor susceptibility factor inAltamente restrito
FUNÇÃO

Precursor of non-enzymatic components of the classical, lectin and GZMK complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system Non-enzymatic component of C3 and C5 convertases (By similarity). Generated following cleavage by complement proteases (C1S, MASP2 or GZMK, depending on the complement pathway), it covalently attaches to the surface of pathogens, where it acts as an opsoni

LOCALIZAÇÃO

SecretedSynapseCell projection, axonCell projection, dendriteCell surface

VIAS BIOLÓGICAS (1)
Regulation of Complement cascade
MECANISMO DE DOENÇA

Systemic lupus erythematosus

A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

OUTRAS DOENÇAS (3)
complement component 4b deficiencyimmunodeficiency due to a classical component pathway complement deficiencysystemic lupus erythematosus
HGNC:1324UniProt:P0C0L5
FCGR3BLow affinity immunoglobulin gamma Fc region receptor III-BMajor susceptibility factor inTolerante
FUNÇÃO

Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils

LOCALIZAÇÃO

Cell membraneSecreted

VIAS BIOLÓGICAS (1)
Neutrophil degranulation
EXPRESSÃO TECIDUAL(Tecido-específico)
Sangue
838.7 TPM
Baço
83.5 TPM
Pulmão
19.8 TPM
Fallopian Tube
5.4 TPM
Adipose Visceral Omentum
3.8 TPM
OUTRAS DOENÇAS (2)
neonatal alloimmune neutropeniasystemic lupus erythematosus
HGNC:3620UniProt:O75015
PDCD1Programmed cell death protein 1Major susceptibility factor inModerado
FUNÇÃO

Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self (PubMed:21276005, PubMed:31754127, PubMed:32184441, PubMed:37208329). Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2 (PubMed:21276005, PubMed:26602187). Following T-cell receptor (TCR) engagement, PDCD1 associates with TCR-CD3 in the immunological synapse and directly inhibits T-cell activation (PubMed:32184441). Suppresses T-c

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (3)
PD-L1(CD274) glycosylation and translocation to plasma membraneCo-inhibition by PD-1Potential therapeutics for SARS
MECANISMO DE DOENÇA

Autoimmune disease, multisystem, infantile-onset, 4

An autosomal recessive immunologic disorder characterized by lymphoproliferative autoimmunity and onset of various autoimmune diseases in early childhood. Death from autoimmune pneumonitis may occur.

EXPRESSÃO TECIDUAL(Tecido-específico)
Linfócitos
23.6 TPM
Baço
11.9 TPM
Coração - Átrio
5.1 TPM
Intestino delgado
4.1 TPM
Pulmão
3.3 TPM
OUTRAS DOENÇAS (2)
autoimmune disease with susceptibility to mycobacterium tuberculosissystemic lupus erythematosus
HGNC:8760UniProt:Q15116
IGHG1Immunoglobulin heavy constant gamma 1Modifying germline mutation inDesconhecido
FUNÇÃO

Constant region of immunoglobulin (Ig) heavy chains. Igs are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound Igs serve as receptors, which upon binding to a specific antigen trigger the clonal expansion and differentiation of B lymphocytes into Ig-secreting plasma cells. Secreted Igs known as antibodies mediate the effector phase of humoral immunity by blocking the interaction of infectious antigens with cellula

LOCALIZAÇÃO

SecretedCell membrane

VIAS BIOLÓGICAS (9)
Role of phospholipids in phagocytosisFCGR3A-mediated IL10 synthesisRegulation of actin dynamics for phagocytic cup formationFCGR activationInitial triggering of complement
MECANISMO DE DOENÇA

Multiple myeloma

A malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia.

EXPRESSÃO TECIDUAL(Ubíquo)
Baço
3470.1 TPM
Pulmão
294.7 TPM
Linfócitos
260.7 TPM
Fallopian Tube
212.2 TPM
Intestino delgado
201.6 TPM
OUTRAS DOENÇAS (2)
systemic lupus erythematosusB-cell chronic lymphocytic leukemia
HGNC:5525UniProt:P01857
BLKTyrosine-protein kinase BlkMajor susceptibility factor inTolerante
FUNÇÃO

Non-receptor tyrosine kinase involved in B-lymphocyte development, differentiation and signaling (By similarity). B-cell receptor (BCR) signaling requires a tight regulation of several protein tyrosine kinases and phosphatases, and associated coreceptors (By similarity). Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation (By similarity). Signaling through BLK plays an important role in transmitting signals through surface immunog

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (1)
RUNX1 regulates transcription of genes involved in BCR signaling
MECANISMO DE DOENÇA

Maturity-onset diabetes of the young 11

A form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease.

OUTRAS DOENÇAS (3)
maturity-onset diabetes of the young type 11systemic lupus erythematosusmaturity-onset diabetes of the young
HGNC:1057UniProt:P51451
IL10Interleukin-10Major susceptibility factor inRestrito
FUNÇÃO

Major immune regulatory cytokine that acts on many cells of the immune system where it has profound anti-inflammatory functions, limiting excessive tissue disruption caused by inflammation. Mechanistically, IL10 binds to its heterotetrameric receptor comprising IL10RA and IL10RB leading to JAK1 and STAT2-mediated phosphorylation of STAT3 (PubMed:16982608). In turn, STAT3 translocates to the nucleus where it drives expression of anti-inflammatory mediators (PubMed:18025162). Targets antigen-prese

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (6)
Interleukin-10 signalingFCGR3A-mediated IL10 synthesisCD163 mediating an anti-inflammatory responseSignaling by ALK fusions and activated point mutantsInterleukin-4 and Interleukin-13 signaling
EXPRESSÃO TECIDUAL(Tecido-específico)
Linfócitos
8.8 TPM
Baço
3.5 TPM
Adipose Visceral Omentum
3.2 TPM
Testículo
2.5 TPM
Pulmão
1.7 TPM
OUTRAS DOENÇAS (6)
systemic lupus erythematosusBehcet diseaseIL10-related early-onset inflammatory bowel diseaserheumatoid arthritis
HGNC:5962UniProt:P22301
C4AComplement C4-AMajor susceptibility factor inAltamente restrito
FUNÇÃO

Precursor of non-enzymatic components of the classical, lectin and GZMK complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system Non-enzymatic component of C3 and C5 convertases (PubMed:8538770). Generated following cleavage by complement proteases (C1S, MASP2 or GZMK, depending on the complement pathway), it covalently attaches to the surface of pathogens, where it acts as an opson

LOCALIZAÇÃO

SecretedSynapseCell projection, axonCell projection, dendriteCell surface

VIAS BIOLÓGICAS (2)
Post-translational protein phosphorylationRegulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
MECANISMO DE DOENÇA

Complement component 4A deficiency

A rare defect of the complement classical pathway associated with the development of autoimmune disorders, mainly systemic lupus with or without associated glomerulonephritis.

OUTRAS DOENÇAS (5)
complement component 4a deficiencyBehcet diseaseimmunodeficiency due to a classical component pathway complement deficiencysystemic lupus erythematosus
HGNC:1323UniProt:P0C0L4
FCGR2BLow affinity immunoglobulin gamma Fc region receptor II-bMajor susceptibility factor inTolerante
FUNÇÃO

Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform II

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (1)
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
MECANISMO DE DOENÇA

Systemic lupus erythematosus

A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
37.7 TPM
Baço
29.0 TPM
Tecido adiposo
17.7 TPM
Adipose Visceral Omentum
14.8 TPM
Intestino delgado
11.9 TPM
OUTRAS DOENÇAS (2)
systemic lupus erythematosusmalaria, susceptibility to
HGNC:3618UniProt:P31994
IRF5Interferon regulatory factor 5Major susceptibility factor inTolerante
FUNÇÃO

Transcription factor that plays a critical role in innate immunity by activating expression of type I interferon (IFN) IFNA and INFB and inflammatory cytokines downstream of endolysosomal toll-like receptors TLR7, TLR8 and TLR9 (PubMed:11303025, PubMed:15695821, PubMed:22412986, PubMed:25326418, PubMed:32433612). Regulates the transcription of type I IFN genes (IFN-alpha and IFN-beta) and IFN-stimulated genes (ISG) by binding to an interferon-stimulated response element (ISRE) in their promoters

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (3)
Interferon gamma signalingInterferon alpha/beta signalingSLC15A4:TASL-dependent IRF5 activation
MECANISMO DE DOENÇA

Inflammatory bowel disease 14

A chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may affect any part of the gastrointestinal tract from the mouth to the anus, but most frequently it involves the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
112.8 TPM
Baço
39.3 TPM
Pulmão
19.5 TPM
Rim - Medula
19.1 TPM
Sangue
18.6 TPM
OUTRAS DOENÇAS (6)
systemic lupus erythematosusprimary biliary cholangitisdiffuse cutaneous systemic sclerosislimited cutaneous systemic sclerosis
HGNC:6120UniProt:Q13568
CR2Complement receptor type 2Major susceptibility factor inTolerante
FUNÇÃO

Serves as a receptor for various ligands including complement component CD3d, HNRNPU OR IFNA1 (PubMed:1849076, PubMed:21527715, PubMed:7753047). When C3d is bound to antigens, attaches to C3d on B-cell surface and thereby facilitates the recognition and uptake of antigens by B-cells (PubMed:21527715). This interaction enhances B-cell activation and subsequent immune responses. Forms a complex with several partners on the surface of B-cells including CD19, FCRL5 and CD81, to form the B-cell corec

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (1)
Regulation of Complement cascade
MECANISMO DE DOENÇA

Systemic lupus erythematosus 9

A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

OUTRAS DOENÇAS (3)
immunodeficiency, common variable, 7systemic lupus erythematosussystemic lupus erythematosus, susceptibility to, 9
HGNC:2336UniProt:P20023
HLA-DRB1HLA class II histocompatibility antigen, DRB1 beta chainMajor susceptibility factor inRestrito
FUNÇÃO

A beta chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the alpha chain HLA-DRA, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DRB1-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells

LOCALIZAÇÃO

Cell membraneEndoplasmic reticulum membraneLysosome membraneLate endosome membraneAutolysosome membrane

VIAS BIOLÓGICAS (7)
Generation of second messenger moleculesTranslocation of ZAP-70 to Immunological synapsePhosphorylation of CD3 and TCR zeta chainsCo-inhibition by PD-1Downstream TCR signaling
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
1832.6 TPM
Pulmão
1234.8 TPM
Baço
990.6 TPM
Intestino delgado
607.2 TPM
Nervo tibial
598.3 TPM
OUTRAS DOENÇAS (16)
narcolepsy-cataplexy syndromefollicular lymphomaVogt-Koyanagi-Harada diseasepediatric multiple sclerosis
HGNC:4948UniProt:P01911

Medicamentos aprovados (FDA)

1 medicamento encontrado nos registros da FDA americana.

💊 PredniSONE (PREDNISONE)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

129 variantes patogênicas registradas no ClinVar.

🧬 ITGAM: NM_000632.4(ITGAM):c.3312C>A (p.Asn1104Lys) ()
🧬 ITGAM: NM_000632.4(ITGAM):c.2977-3C>G ()
🧬 ITGAM: GRCh37/hg19 16p11.2(chr16:30907349-31334236)x1 ()
🧬 ITGAM: NM_000632.4(ITGAM):c.3313C>G (p.Pro1105Ala) ()
🧬 ITGAM: NM_000632.4(ITGAM):c.1083+6T>G ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 204 variantes classificadas pelo ClinVar.

122
82
Patogênica (59.8%)
VUS (40.2%)
VARIANTES MAIS SIGNIFICATIVAS
DNASE1L3: NM_004944.4(DNASE1L3):c.566A>G (p.Asp189Gly) [Likely pathogenic]
DNASE1L3: NM_004944.4(DNASE1L3):c.401_402dup (p.Phe135fs) [Likely pathogenic]
PLD4: PLD4, TYR248CYS [Pathogenic]
PLD4: PLD4, 1-BP DEL, 1088G [Pathogenic]
PLD4: PLD4, ARG201GLN [Pathogenic]

Vias biológicas (Reactome)

102 vias biológicas associadas aos genes desta condição.

Toll Like Receptor 4 (TLR4) Cascade Cell surface interactions at the vascular wall Integrin cell surface interactions Interleukin-4 and Interleukin-13 signaling Neutrophil degranulation FCGR activation Regulation of actin dynamics for phagocytic cup formation Role of phospholipids in phagocytosis FCGR3A-mediated IL10 synthesis Initial triggering of complement Classical antibody-mediated complement activation Regulation of Complement cascade Dengue virus activates/modulates innate and adaptive immune responses Transport and metabolism of PAPS Inorganic anion exchange by SLC26 transporters Synthesis of PG Synthesis of IP3 and IP4 in the cytosol PINK1-PRKN Mediated Mitophagy Regulation of TNFR1 signaling Regulation of necroptotic cell death Synthesis of active ubiquitin: roles of E1 and E2 enzymes E3 ubiquitin ligases ubiquitinate target proteins Antigen processing: Ubiquitination & Proteasome degradation NOD1/2 Signaling Pathway TNFR1-induced proapoptotic signaling TNFR1-induced NF-kappa-B signaling pathway Ovarian tumor domain proteases Negative regulators of DDX58/IFIH1 signaling Sphingolipid catabolism TNFs bind their physiological receptors Regulation by TREX1 IRF3-mediated induction of type I IFN Trafficking and processing of endosomal TLR Toll Like Receptor 7/8 (TLR7/8) Cascade Regulation of TLR by endogenous ligand Potential therapeutics for SARS SARS-CoV-1 activates/modulates innate immune responses SARS-CoV-2 activates/modulates innate and adaptive immune responses TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation MyD88 dependent cascade initiated on endosome Defective regulation of TLR7 by endogenous ligand RSV-host interactions Interleukin-20 family signaling Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation Interleukin-35 Signalling Interleukin-12 signaling Interleukin-23 signaling Interleukin-21 signaling Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) Phosphorylation of CD3 and TCR zeta chains Translocation of ZAP-70 to Immunological synapse PXKLP-K305-CSAD dimer PXKLP-K305-CSAD decarboxylates 3-sulfinoalanine to hypotaurine Transcriptional Regulation by MECP2 Loss of MECP2 binding ability to 5hmC-DNA Loss of phosphorylation of MECP2 at T308 Loss of MECP2 binding ability to the NCoR/SMRT complex Loss of MECP2 binding ability to 5mC-DNA Regulation of MECP2 expression and activity MECP2 regulates neuronal receptors and channels MECP2 regulates transcription of neuronal ligands MECP2 regulates transcription factors MECP2 regulates transcription of genes involved in GABA signaling Nuclear events stimulated by ALK signaling in cancer Oncogene Induced Senescence PIP3 activates AKT signaling MyD88:MAL(TIRAP) cascade initiated on plasma membrane p75NTR recruits signalling complexes NF-kB is activated and signals survival TAK1-dependent IKK and NF-kappa-B activation activated TAK1 mediates p38 MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Interleukin-1 signaling IRAK1 recruits IKK complex IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation MyD88 cascade initiated on plasma membrane DNASE1L1 DNASE1L1 Co-stimulation by CD28 Co-inhibition by CTLA4 RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) Activation of C3 and C5 Post-translational modification: synthesis of GPI-anchored proteins Co-inhibition by PD-1 PD-L1(CD274) glycosylation and translocation to plasma membrane FCGR3A-mediated phagocytosis RUNX1 regulates transcription of genes involved in BCR signaling Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Interleukin-10 signaling CD163 mediating an anti-inflammatory response Signaling by ALK fusions and activated point mutants Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Post-translational protein phosphorylation Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Interferon gamma signaling Interferon alpha/beta signaling SLC15A4:TASL-dependent IRF5 activation Downstream TCR signaling Generation of second messenger molecules MHC class II antigen presentation

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado2
3Fase 31
2Fase 23
1Fase 18
·Pré-clínico6
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Lúpus eritematoso sistêmico

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

20 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT07219563 · Alnuctamab for Refractory SLE (LATTE Study)Recrutando
PHASE1
NCT03816345 · Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Ad…Recrutando
PHASE1
NCT06314282 · INTERSTELLAR - International Study Evaluating Lupus Outcomes…Recrutando
NCT07276958 · A Study of LY4298445 in Healthy Participants and Participant…Recrutando
PHASE1
NCT06659029 · Prospective Registry Investigating Maternal and Infant Outco…Recrutando
NCT05567198 · Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Pr…Recrutando
NCT07526350 · MTS109 in Patients With Refractory Autoimmune DiseasesRecrutando
EARLY_PHASE1
NCT07087912 · Safety and Immunogenicity of the Live Attenuated Tetravalent…Recrutando
PHASE4
NCT05934149 · Lupus Landmark Study: A Prospective Registry and Bioreposito…Recrutando
NCT06434363 · Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and…Recrutando
PHASE1, PHASE2
NCT07323173 · A Phase I Study to Assess LBL-047 in Healthy Adults and Pati…Recrutando
PHASE1
NCT07193810 · A Study of CC312 for Relapsed/Refractory Autoimmune DiseasesRecrutando
EARLY_PHASE1
NCT06594068 · Prospective Registry Investigating Maternal, Infant, and Lac…Recrutando
PHASE4
NCT06801119 · Efficacy and Safety of HN2301 in Autoimmune Diseases(AIDs)Recrutando
PHASE1
NCT07523542 · SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refr…Recrutando
PHASE1, PHASE2
NCT06673043 · Anifrolumab Real-world Treatment Outcomes in Systemic Lupus …Recrutando
NCT05835986 · A First-in-Human Study to Investigate the Safety, Tolerabili…Recrutando
PHASE1
NCT07175285 · A Study in Participants With Active Systemic Lupus Erythemat…Recrutando
NCT07438496 · A Study of Nipocalimab in Adults With Moderate to Severe Sys…Recrutando
PHASE3
NCT06121297 · RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safe…Recrutando
PHASE1, PHASE2

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

📖Melhor nível de evidência: Revisão
Timeline de publicações
29.664 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 29.664

#1

Magnetic Resonance Imaging-Negative Lupus Myelitis: A Narrative Review.

Annals of Indian Academy of Neurology2026 Mar 24

Magnetic resonance imaging (MRI)-negative lupus myelitis (MNLM) is a rare neurological manifestation of systemic lupus erythematosus (SLE). Diagnosing MNLM without prior systemic involvement remains challenging. This review aims to analyze all published cases and compare MNLM patients with (Group A) and without prior SLE diagnosis (Group B), emphasizing on demographic and clinical profiles, treatment, and outcomes. A PubMed literature review on MNLM was conducted. Demographic profile, clinical presentations, and management were analyzed. MNLM patients were categorized into Group A and B and compared using univariate and multivariate comparison methods, where a P value <0.05 was considered significant. In total, 41 cases were analyzed. The cohort was predominantly female (8:1 ratio, mean age 31.22 ± 11.91 years, range 15-59 years). Thoracic cord involvement was the most common (55%), with myelitis presenting as the first manifestation in 49% of patients. Clinical presentations were predominantly subacute (71%) with partial tract involvement in 63%. Group A demonstrated significantly higher cervical cord localization (P = 0.019) compared to Group B's thoracic involvement (P = 0.041). Antiphospholipid syndrome (APS) antibody-positive patients showed 3.2-fold higher odds for partial recovery (P = 0.16). Logistic regression analysis identified Anti Smith/ Ribonucleoprotein/ Ribosomal (Sm/RNP/Rib) antibodies as independent risk factors for poor complete recovery (odds ratio (OR) = 0.61), whereas cervical cord localization independently improved odds for complete recovery (OR = 3.2). MNLM presents with variable clinical manifestations suggesting selective tract involvement. Group A exhibits higher cervical involvement, while Group B shows predominantly thoracic involvement. APS antibodies favor partial recovery, cervical localization predicts complete recovery, and Sm/RNP/Rib antibodies are independent predictors of poor recovery outcomes.

#2

Long-term outcomes of hydroxychloroquine dose reduction in Puerto Ricans with systemic lupus erythematosus: 6-year follow-up.

Lupus science &amp; medicine2026 Mar 24

To reduce the risk of hydroxychloroquine (HCQ)-induced retinopathy, the American Academy of Ophthalmology recommends a maximum HCQ dose of ≤5.0 mg/kg/day. Previously, we reported that reducing HCQ to this threshold did not affect clinical outcomes in Puerto Rican patients with systemic lupus erythematosus (SLE) after 2 years. To evaluate longer term effects, we extended follow-up to 6 years post-HCQ dose adjustment. We conducted a retrospective study on a cohort of Puerto Rican SLE patients whose HCQ doses were adjusted to ≤5.0 mg/kg/day. Disease activity (per-Systemic Lupus Erythematosus Disease Activity Index), lupus exacerbations, hospitalisations, disease damage (per SLICC/ACR Damage Index) and pharmacologic treatments were assessed. Outcomes during the 4-year extension were compared with preadjustment and initial 2-year postadjustment periods. A control group of SLE patients who did not require HCQ dose adjustment was also included. Among the 304 patients included in the study, 60 required HCQ dose adjustment, whereas 244 patients did not require modification of their HCQ regimen and served as controls. During the 4-year extension period, a small but statistically significant increase in disease damage was observed in patients who underwent HCQ dose adjustment compared with earlier follow-up periods. Tacrolimus exposure significantly increased, whereas other immunosuppressive therapies remained stable. No increase in disease activity, lupus exacerbations or hospitalisations was observed. Clinical features were comparable between patients who underwent HCQ dose adjustment and those who did not, although patients in the adjusted-dose group had lower weight-based daily HCQ dosing and were less likely to develop HCQ-induced retinopathy. In this cohort, reducing HCQ to ≤5.0 mg/kg/day was associated with a slight increase in long-term disease damage. No adverse outcomes on disease activity, exacerbations or hospitalisations were observed, supporting the long-term safety of HCQ dose adjustment in Puerto Rican SLE patients.

#3

'Getting comfortable with the uncomfortable': barriers, facilitators and influences on reproductive health discussions from Hispanic women with systemic lupus erythematosus in the USA - a qualitative study.

Lupus science &amp; medicine2026 Mar 24

Systemic lupus erythematosus (SLE) primarily affects women of reproductive age, necessitating complex conversations surrounding pregnancy and contraception use. Hispanic women in the USA bear a disproportionate and severe burden of SLE, facing language and cultural barriers to care, and higher rates of unplanned pregnancy and under-representation in reproductive health research. This study explores patient-reported barriers and facilitators to reproductive health conversations as well as their attitudes and perceptions on how these conversations can be improved. We conducted 30 semistructured interviews in both English and Spanish with Hispanic women aged 18-45 with SLE. Participants were recruited from Los Angeles General Medical Center and Lupus LA. Eligible participants were heterosexually active or considering pregnancy within 3 years. Interviews were analysed using grounded theory to identify themes related to barriers and facilitators in clinical reproductive health interactions. Three major themes emerged: (1) barriers to reproductive health conversations were often driven by competing clinical priorities as well as discomfort discussing sensitive topics; (2) facilitators to reproductive health conversations included the presence of genuine clinician-patient rapport, well-controlled disease activity and patient proactiveness; (3) areas of improvement included both a more encompassing and thorough data-driven approach to reproductive health discussions throughout disease course. Findings reported herein underscore the importance of early, individualised reproductive health counselling for women with SLE. Enhanced clinician communication with sensitive topics, refined patient education and frequent interdisciplinary collaboration can help address the emotional, medical and informational needs of Hispanic women with SLE navigating reproductive decisions.

#4

Clinical, laboratory, and histopathological characteristics of pediatric lupus nephritis: a retrospective study in a national referral center in Mexico.

Frontiers in pediatrics2026

Pediatric lupus nephritis (LN) remains a major cause of morbidity and mortality, yet data from Latin American populations are limited. This study aimed to describe the clinical, laboratory, and histopathological characteristics of pediatric LN and identify prognostic factors associated with renal replacement therapy (RRT). We conducted a retrospective cross-sectional study including patients <18 years of age with LN diagnosed between 2020 and 2024 at a national referral center in Mexico. Demographic, clinical, immunological, histopathological, and therapeutic variables at diagnosis were analyzed. Multivariable logistic regression was performed to identify predictors of RRT. Eighty patients were included (83% female; mean age 15.1 ± 2.8 years). Median proteinuria was 41 mg/m²/h; hematuria and leukocyturia were present in 46% and 26% of patients, respectively. All patients were ANA positive, with frequent hypocomplementemia and elevated anti-double-stranded DNA titers. Among biopsied patients, class IV was the most common histological subtype (60%). Proliferative forms were associated with reduced glomerular filtration rate (<90 mL/min/1.73 m²; p = 0.012) and higher activity index scores (p = 0.04), while chronicity indices were low. Fifteen patients (18.8%) required RRT, and mortality was 6.25%. In multivariable analysis, hypoalbuminemia (<2.5 g/dL) was independently associated with RRT (OR 6.04; 95% CI 1.33-27.50; p = 0.020). This study represents one of the largest pediatric LN cohorts reported from Mexico. Proliferative forms were associated with greater inflammatory activity and impaired renal function at diagnosis. Hypoalbuminemia emerged as a simple and accessible biomarker for early risk stratification of severe renal outcomes.

#5

Advances in endoplasmic reticulum stress response in immune-associated skin diseases: Mini-review.

Tissue &amp; cell2026 Mar 18

The skin protects the body from external allergens and pathogens. Disruption of the physiological state of the skin is a hallmark of many immune-associated skin disorders and is well-characterized in disease states such as psoriasis, vitiligo, and systemic lupus erythematosus (SLE). The endoplasmic reticulum (ER) is a crucial organelle within the cell responsible for functions such as protein synthesis, modification and folding. Endoplasmic reticulum stress (ERS) is characterized as an intracellular condition of stress that typically arises from aberrant protein synthesis or environmental changes. Various stimuli such as ischemia, hypoxia, and oxidative stress can trigger ERS, resulting in the misfolding of newly synthesized proteins and the activation of the unfolded protein response (UPR). Emerging evidence indicates that UPR signaling modules have fundamental roles in multiple physiological processes beyond the homeostatic control of protein folding including the pathogenesis of several immune-related skin disorders. We summarize the potential role of ER stress and the UPR in immune-associated skin diseases. This review aims to explore the mechanisms underlying ERS response in these immune-associated skin diseases, offering valuable insights for further research. Understanding the molecular mechanism of UPR activation and ER stress may represent a novel target for drug discovery and innovative therapeutic strategies in the context of immune-associated skin diseases.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC38.990 artigos no totalmostrando 197

2026

Two-Sample Bidirectional Mendelian Randomization Analysis of the Causal Relationship Between Immune Cell Phenotypes and Systemic Lupus Erythematosus.

Clinical, cosmetic and investigational dermatology
2026

Libman-Sacks Endocarditis Presenting as Severe Mitral Stenosis.

CASE (Philadelphia, Pa.)
2026

Integrative Use of Belimumab and Individualized Traditional Chinese Medicine in Refractory Pediatric Lupus Nephritis: A Case Report.

Journal of inflammation research
2026

Prevalence and Risk Factors of Systemic Lupus Erythematosus in Patients With Chronic Cutaneous Lupus: A Bicentric Study Employing Three Classification Criteria.

International journal of dermatology
2026

Diagnostic classification of dermatomyositis with and without electrodiagnostic study: real-world clinical practice.

Singapore medical journal
2026

Magnetic Resonance Imaging-Negative Lupus Myelitis: A Narrative Review.

Annals of Indian Academy of Neurology
2026

Long-term outcomes of hydroxychloroquine dose reduction in Puerto Ricans with systemic lupus erythematosus: 6-year follow-up.

Lupus science &amp; medicine
2026

'Getting comfortable with the uncomfortable': barriers, facilitators and influences on reproductive health discussions from Hispanic women with systemic lupus erythematosus in the USA - a qualitative study.

Lupus science &amp; medicine
2026

Tapering strategies for immunosuppressive, corticosteroid, and biologic therapy in lupus nephritis: a national survey of rheumatology and nephrology practices in Saudi Arabia.

Rheumatology international
2026

Taurine supplementation and systemic lupus erythematosus in preclinical studies: a systematic review of clinical outcomes and underlying mechanisms.

Amino acids
2026

Frequency and clinical associations of Epstein-Barr virus molecular detection in systemic lupus erythematosus: A follow-up study.

Lupus
2026

Evaluation of Anti-dsDNA Antibodies in Laboratory Practice: Management of Different Analytical Methods and Correlation with HEp-2 Immunofluorescence Patterns.

Antibodies (Basel, Switzerland)
2026

Therapeutic Potential of Stem Cells From Human Exfoliated Deciduous Teeth and Their Derivatives in Immune-Mediated Inflammatory Diseases: Mechanisms and Perspectives.

Advanced biology
2026

The research progress on the role of glucose-6-phosphate dehydrogenase in immune regulation.

PeerJ
2026

Epstein-Barr Virus Transformed B Cells From Systemic Lupus Erythematosus and Multiple Sclerosis Patients Differ in EBV Lytic and Latency Marker Expression.

Immunity, inflammation and disease
2026

Targeting JAK/STAT Signaling with Cold Atmospheric Plasma: A Potential Therapy for Systemic Lupus Erythematosus.

Expert reviews in molecular medicine
2026

Efficacy of telitacicept in a refractory systemic lupus erythematosus patient with lupus nephritis and subsequent pregnancy: a case-based review.

Clinical rheumatology
2026

Recent advances in the pathogenesis of Neuropsychiatric systemic lupus erythematosus.

Expert review of clinical immunology
2026

Efficacy and safety of belimumab in IgA nephropathy: real-world evidence.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
2026

Distinct Interferon and Intracellular Signaling Signatures in Systemic Lupus Erythematosus and Dermatomyositis by Integrative Transcriptomic and Proteomic Analysis.

ACR open rheumatology
2026

Systemic lupus erythematosus-related infections in pregnancy: a cross-sectional bibliometric analysis.

Rheumatology international
2026

A proposal for the implementation of telemedicine in Japan for rheumatoid arthritis, juvenile idiopathic arthritis, and systemic lupus erythematosus: review article.

Modern rheumatology
2026

Subsets of Lupus Patients Identified by Gene Expression Profiles Exhibit Differential Clinical Responsiveness to Baricitinib.

Arthritis &amp; rheumatology (Hoboken, N.J.)
2026

Hydroxychloroquine-Use and Preeclampsia and Preterm Delivery Complications in Systemic Lupus Erythematosus Pregnancies: Is there a protective effect?

Arthritis care &amp; research
2026

When Lupus Hits the Spine: A Case of Extensive Transverse Myelitis.

Irish medical journal
2026

MZB1 at the ER-immunity interface: from antibody folding to disease vulnerability in autoimmunity, inflammation, and cancer.

Journal of Cancer
2026

Persistent cutaneous lupus erythematosus: A pathway toward systemic disease?

Journal of translational autoimmunity
2026

Renal macrophage TLR7 signaling in lupus nephritis: from pathogenic mechanisms to therapeutic opportunities.

Frontiers in immunology
2026

IFNγ-associated immune-metabolic remodeling is linked to serotonin-kynurenine imbalance and cortical vulnerability in lupus-prone mice.

Frontiers in immunology
2026

The IDO1/AhR-HIF-1α metabolic axis: ARNT competition as a central antagonistic switch in autoimmune pathogenesis.

Frontiers in immunology
2026

Floating Thrombus as an Underdiagnosed Etiology for Stroke: A Case Series.

Cureus
2026

Clinical value of combined serum galectin-9 and urine MCP-1 testing for assessment of systemic lupus erythematosus disease activity and early diagnosis of lupus nephritis.

American journal of translational research
2026

Case Report: Lung squamous cell carcinoma mimicking recurrent aspergillosis in systemic lupus erythematosus.

Frontiers in medicine
2026

Atypical Bilobed Lymphocytes in CSF: Diagnostic Insights into Varicella Zoster Virus Meningitis and Herpes Zoster with Temporal Presentations.

Infection and drug resistance
2026

Clinical, laboratory, and histopathological characteristics of pediatric lupus nephritis: a retrospective study in a national referral center in Mexico.

Frontiers in pediatrics
2026

Mechanistic insights into B-cell activation and autoreactivity regulation in active SLE and remission.

bioRxiv : the preprint server for biology
2026

Anifrolumab in Refractory Oral Manifestations in Systemic Lupus Erythematosus: A Case Report and Literature Review.

Biologics : targets &amp; therapy
2026

CYBB-Mediated Ferroptosis Drives Podocyte Injury in Lupus Nephritis and Represents a Therapeutic Target.

Journal of inflammation research
2026

Lupus Enteritis as an Initial Manifestation in a Previously Undiagnosed Case of Systemic Lupus Erythematosus: A Case Report.

The Indian journal of radiology &amp; imaging
2026

LUNELORD: A descriptive, prospective study on the demographics, disease characteristics and health-related quality of life of patients with LUpus NEphritis and long-term ORgan damage in rheumatology clinics in the Arabian Gulf.

Lupus
2026

SLAMF1 at the crossroads of immunity and disease: Biology, pathology, and therapeutic opportunities.

Cytokine
2026

An analysis of clinical manifestations and therapeutic outcomes in pediatric connective tissue disease-associated interstitial lung disease.

Pediatric rheumatology online journal
2026

Advances in endoplasmic reticulum stress response in immune-associated skin diseases: Mini-review.

Tissue &amp; cell
2026

The Relationship Between Climate Change and Rheumatic Disease: A Review.

International archives of allergy and immunology
2026

Genetic association of Angiopoietin-2 rs12674822 and rs3739390 polymorphisms with systemic lupus erythematosus risk: a preliminary single-center study in Egyptian patients.

Journal of immunoassay &amp; immunochemistry
2026

Limited Access to Systemic Lupus Erythematosus: A Systematic Review.

Current rheumatology reviews
2026

The Auditory Manifestations of Autoimmune Rheumatologic Diseases: A Review of Current Evidence.

Current rheumatology reviews
2026

Microbiota-driven Immunopathogenesis in Systemic Lupus Erythematosus: Cross-site Mechanisms and Intervention Strategies.

Current molecular medicine
2026

Serum epitope-specific anti-recoverin autoantibodies as biomarkers for lupus retinopathy.

Arthritis research &amp; therapy
2026

An immunometabolic signature of major depressive disorder in systemic lupus erythematosus.

Annals of the rheumatic diseases
2026

Diffuse alveolar hemorrhage in systemic lupus erythematosus during the COVID-19 era-a retrospective analysis with mechanistic investigation.

Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
2026

Divergent comorbidity profiles in neuromyelitis optica spectrum disorder and multiple sclerosis: A large single-centre cohort from Turkey.

Multiple sclerosis and related disorders
2026

microRNA-155: a versatile noncoding RNA.

Molecular biology reports
2026

B cell receptor signaling in autoimmune rheumatic diseases: regulatory mechanisms and therapeutic targeting.

Frontiers in immunology
2026

Belimumab-induced remission in refractory lupus mesenteric vasculitis: a case report with 49-month follow-up.

Frontiers in immunology
2026

Unveiling biomarkers of telitacicept's efficacy in SLE treatment through proteomics and metabolomics.

Frontiers in immunology
2026

Immunopathogenesis of accelerated atherosclerosis in systemic lupus erythematosus: from innate and adaptive dysregulation to clinical implications.

Frontiers in immunology
2026

Increased apathy level in systemic lupus erythematosus.

Clinical rheumatology
2026

Risk factor of osteoporosis in systemic lupus erythematosus patients: a cross-sectional study in a tertiary hospital in Indonesia.

Lupus science &amp; medicine
2026

[Perspectives and strategic approaches on unmet therapeutic needs in systemic lupus erythematosus].

Zhonghua yi xue za zhi
2026

Anifrolumab in systemic lupus erythematosus: real-world evidence from a Spanish multicentre cohort of 206 patients and literature review.

RMD open
2026

Anti-CD19 CAR T cell therapy for refractory SLE-ITP.

Med (New York, N.Y.)
2026

GBP2 promotes podocyte pyroptosis and contributes to the pathogenesis of pediatric lupus nephritis.

PloS one
2026

Gut and oral microbiota characterized in systemic lupus erythematosus patients from India: A pilot study.

Lupus
2026

Multidisciplinary advances in oral health management in patients with systemic lupus erythematosus: a comprehensive review.

Quintessence international (Berlin, Germany : 1985)
2026

A Case of Disseminated Trichophytosis With Vascular Invasion and Multiple Ulcers: Case Report and Literature Review.

The Journal of dermatology
2026

Scavenging of Isolevuglandins Attenuates Neutrophil Migration and Neutrophil Extracellular Trap Formation in Systemic Lupus Erythematosus.

ACR open rheumatology
2026

Cellular therapies for rheumatic disease.

Current opinion in rheumatology
2026

Impact of Cervical Radiculopathy on the Risk of Cubital Tunnel Syndrome Following Distal Humerus Fracture: A Retrospective Cohort Analysis of 165 Million Patients.

Hand (New York, N.Y.)
2026

Characterizing the effects of genetic liability to autoimmune conditions on pregnancy outcomes using Mendelian randomization.

BMC medicine
2026

Prasugrel inhibits TLR7-driven autoimmunity in systemic lupus erythematosus by acetylating cGAS.

Nature communications
2026

Neutrophil transcriptomics in SLE reveals intrinsic disease signatures, shared ex vivo adaptation, and transcriptional reset after CAR T-cell therapy.

Annals of the rheumatic diseases
2026

Twelve-month follow-up after telitacicept withdrawal in patients with SLE: a single-centre study.

Lupus science &amp; medicine
2026

Outcomes of Transcatheter Aortic Valve Replacement in Patients with Rheumatologic Diseases: A Large-Scale Propensity-Matched Analysis.

The American journal of the medical sciences
2026

Rapid response of pyoderma gangrenosum associated with systemic lupus erythematosus to anifrolumab.

Medicina clinica
2026

Comorbidities in Discoid Lupus: A Systematic Review and Meta-analysis of Prevalence and Association.

Dermatology and therapy
2026

Bone microarchitecture impairment in juvenile systemic lupus erythematosus patients: A comparative study.

Lupus
2026

Cytomegalovirus Infection Mimics Manifestations of Underlying Diseases in Patients With Autoimmune Disorders: A Case Report and Literature Review.

Immunity, inflammation and disease
2026

Hydroxychloroquine withdrawal triggers pregnancy-associated pulmonary arterial hypertension in systemic lupus erythematosus: a case report and exploration of the Complement-EndMT axis.

Frontiers in pharmacology
2026

Vitamin D3 as an immunomodulatory agent: molecular mechanisms, clinical translation, and precision therapeutic strategies.

Frontiers in immunology
2026

Novel TLR7 gain-of-function variant and review of the associated disease spectrum.

Journal of human immunity
2026

Acute Myocardial Infarction Secondary to Triple Vessel Coronary Artery Disease in a 31-year-old Female with Systemic Lupus Erythematosus: Case Report and Review of Literature.

Acta medica Philippina
2026

Elevated Peripheral CD161+ Treg Cells and Their Clinical Significance in Behçet Syndrome.

ACR open rheumatology
2026

HLA - C*03:02:02 and DPA1*01:03:01 protect against discoid rash in Thai Systemic Lupus Erythematosus patients.

Scientific reports
2026

Comparative 1H NMR Lipoprotein Profiling of Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients Highlights Disease-Specific Lipoprotein Dysregulation.

Journal of proteome research
2026

The crosstalk between iron metabolism and immune tolerance in autoimmunity.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]
2026

Systemic Lupus Erythematosus and Epstein-Barr Virus: Recent Discoveries and Open Questions.

Clinical chemistry
2026

Central memory T cells: stem-like biology, pathogenic roles in autoimmunity, and therapeutic applications.

Clinical and experimental rheumatology
2026

Clinical and immunologic status of a child conceived following maternal administration of CD19 CAR T-cells for systemic lupus erythematosus.

Clinical and experimental rheumatology
2026

Systemic lupus erythematosus: one year in review 2026.

Clinical and experimental rheumatology
2026

SLE-diseaseome: a comprehensive meta-collection of systemic lupus erythematosus relevant functional pathways.

Bioinformatics advances
2026

Long-term follow-up in a patient with Purtscher-like retinopathy associated with systemic lupus erythematosus.

Korean journal of ophthalmology : KJO
2026

Increased soluble CD200 in serum of SLE patients does not reflect disease activity or affect CD200R1 function in T cells.

Arthritis research &amp; therapy
2026

Hargraves Remembered: Bone Marrow L.E. Cells as a Clue to Active Systemic Lupus Erythematosus.

Mayo Clinic proceedings
2026

The impact of anti-SSA/Ro antibodies on pregnancy outcomes in patients with systemic lupus erythematosus.

Rheumatology (Oxford, England)
2026

Severe systemic lupus erythematosus with thrombotic microangiopathy: rescue therapy with pegcetacoplan.

Pediatric nephrology (Berlin, Germany)
2026

Recent Advances in Multi-Omics of Systemic Lupus Erythematosus.

Current rheumatology reviews
2026

Cardiogenic shock treated effectively by Berlin Heart implantation in a young patient with systemic lupus erythematosus.

Kardiologia polska
2026

Advances in the study of low-density neutrophils in rheumatic diseases.

Frontiers in immunology
2026

Shared immune dysregulation in systemic lupus erythematosus and colorectal cancer: a multi-omics guided discovery of DNASE1L3-centric efferocytosis deficiency.

Frontiers in immunology
2026

Bone marrow mesenchymal stromal cells metabolic reprogramming in systemic lupus erythematosus: remodeling of bone marrow microenvironment and regulation of immune cell fate.

Frontiers in immunology
2026

Pericarditis in Patients with Autoimmune Disease: Insights into Prevalence and Optimal Management.

Methodist DeBakey cardiovascular journal
2026

[Clinical Manifestations of Childhood Systemic Lupus Erythematosus-associated Acute Pancreatitis and Evaluation of the Efficacy of Plasma Exchange Combined With Glucocorticoids].

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
2026

Phenotypic profiling of pristane-induced mimicking human systemic lupus erythematosus in Macaca fascicularis.

Animal models and experimental medicine
2026

[Systemic lupus erythematosus in a child complicated with Fabry disease].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2026

B-cell monitoring predicts infection risk in childhood systemic lupus erythematosus patients on belimumab.

Rheumatology (Oxford, England)
2026

IL-33 is Required for Behavioral Deficits in a Murine Model of Systemic Lupus Erythematosus Through Regulation of Microglia Glycolysis.

CNS &amp; neurological disorders drug targets
2026

Bullous Systemic Lupus Erythematosus in a Southeast Asian Cohort: High Systemic Association Driving Systemic Therapy.

Asian Pacific journal of allergy and immunology
2026

Delayed Recognition of Systemic Lupus Erythematosus Presenting With Visceral Muscle Dysmotility and Chronic Mucus-Bloody Enteropathy: A Case Report.

The American journal of case reports
2026

Optic nerve head microcirculation on optical coherence tomography angiography is reduced in systemic lupus erythematosus and relates to nailfold videocapillaroscopy phenotypes: a cross-sectional case-control study.

Clinical rheumatology
2026

Co-occurrence of systemic lupus erythematosus and myasthenia gravis: Insights from a cross-sectional cohort.

Clinical neurology and neurosurgery
2026

Unique brain mechanisms in early events in SLE with diffuse neuropsychiatric disease (NPSLE): Implications for the management.

Lupus
2026

Knockdown of LncRNA NIFK-AS1 inhibits the activation of CD4 + T cells in systemic lupus erythematosus by regulating the let-7f-5p/STAT3 axis.

Immunologic research
2026

Evaluation of cardiovascular morbidities in children and adolescents with lupus nephritis from south India: A cross-sectional analytical study.

Lupus
2026

One-Step Multiplex PCR Reveals Selective Activation of Immunostimulatory Human Endogenous Retroviruses and Epigenetic Imbalance in Systemic Lupus Erythematosus.

International journal of molecular sciences
2026

Advances in Diagnosing and Managing Primary Systemic Vasculitides: A Transforming Landscape.

Diagnostics (Basel, Switzerland)
2026

Glycomic Profiles of IgG, C3 and Alpha-1-Acid Glycoprotein (AGP) Before and One Year After Treatment for Active Lupus Nephritis.

Cells
2026

Profiling miRNA in Systemic Lupus Erythematosus Patients Adhering to a Mediterranean Diet: An Interventional Pilot Study.

Journal of clinical medicine
2026

Recurrence and Outcomes of Lupus Nephritis After Renal Transplantation: Analysis of Nine Cases and Review of the Literature.

Journal of clinical medicine
2026

Acute rheumatic fever or rheumatoid arthritis? The role of hydroxychloroquine: a case report.

Journal of medical case reports
2026

Correlation between anti-retinal antibodies and lupus retinopathy in systemic lupus erythematosus.

Scientific reports
2026

Hyposplenism in systemic lupus erythematosus: biological and radiological characteristics and its association with increased risk of infection.

RMD open
2026

Left Ventricular Mass Index as an independent predictor of major adverse cardiovascular and cerebrovascular events in patients with SLE.

Lupus science &amp; medicine
2026

P2 purinergic receptors in systemic lupus erythematosus: from experimental findings to therapeutic perspectives.

Current opinion in immunology
2026

'Water Target Sign' on CT Scan in Systemic Lupus Erythematosus: Author's Reply.

Indian journal of pediatrics
2026

Clinical characteristics and diagnostic indicators of childhood-onset systemic lupus erythematosus complicated with macrophage activation syndrome.

Clinical rheumatology
2026

Shrinking lung syndrome in systemic lupus erythematosus: Insights from a case series and a systematic review of the past decade.

Lupus
2026

Non-Coding Regulatory Variants in Autoimmune Disease: Biological Mechanisms, Immune Context, and Integrative Multi-Omics Interpretation.

Biology
2026

Efficacy of Low-dose Aspirin in Preventing Hypertensive Disorders of Pregnancy in Women with Systemic Lupus Erythematosus: A Single-Center Retrospective Cohort Study.

Modern rheumatology
2026

Predictive value of interferon regulatory factor 5 nuclear translocation in B cells for disease activity and flare in systemic lupus erythematosus: a prospective observational cohort study.

Modern rheumatology
2026

Symptomatic Spontaneous Intracranial Hypotension Caused by a Cerebrospinal Fluid Leak at the C1-C2 Level of the Spine Sealed With an Epidural Blood Patch-Case Series and Review of Literature.

Pain practice : the official journal of World Institute of Pain
2026

Palmar Cutaneous Erythematous Macules: A Case Report of an Atypical Presentation of Chilblain Lupus Erythematosus.

Cureus
2026

The emerging role of histone acetylation in rheumatic diseases: unraveling mechanisms and therapeutic prospects.

Frontiers in immunology
2026

Bidirectional Mendelian Randomization Analysis Reveals Causal Associations Between Autoimmune Diseases and Colorectal Cancer.

World journal of oncology
2026

Development of a PERMA-Based Intervention Program to Address Fear of Disease Progression in Systemic Lupus Erythematosus: A Delphi Consensus Study.

Journal of multidisciplinary healthcare
2026

Hematopoietic Stem Cell Transplantation in Rheumatic Diseases.

International journal of rheumatic diseases
2026

Inverse association between hydroxychloroquine use and depressive symptoms in systemic lupus erythematosus: a single-center cross-sectional study.

BMC rheumatology
2026

Monogenic lupus with SLC7A7 mutations: a retrospective study from a Chinese center.

Orphanet journal of rare diseases
2026

Serum IL-2 levels are associated with disease activity and related to dyslipidaemia and the immunological profile in systemic lupus erythematosus.

Lupus science &amp; medicine
2026

Cross-tissue integrative transcriptomic and multimodal analyses suggest shared immune signatures linking lupus nephritis and cutaneous lupus erythematosus.

Frontiers in immunology
2026

The role of programmed cell death 1 in autoimmune diseases: mechanisms and therapeutic implications.

Frontiers in immunology
2026

Sexual dimorphism of early GPR183-dependent B cell responses in systemic lupus erythematosus.

iScience
2026

Demographic and conceptual disparities in systemic lupus erythematosus: A comparative analysis from Riyadh, Saudi Arabia.

Journal of family medicine and primary care
2026

A novel epigenetic regulation of JAM-A by EZH2-DNMT3A cascade contributes to T cell adhesion via the activation of Rap1a in lupus patients.

Journal of translational autoimmunity
2026

Analysis of the impact of pharmacological treatment on arterial stiffness in patients with connective tissue diseases.

American heart journal plus : cardiology research and practice
2026

Systemic Lupus Erythematosus With IgA Nephropathy: Challenges in Diagnosis and Management.

The American journal of case reports
2026

From Treg, FOXP3 to RBPJ: Linking basic science and clinical medicine.

Taiwanese journal of obstetrics &amp; gynecology
2026

Pulmonary Involvement in ANCA-associated Vasculitis Overlapping with Long-standing Systemic Lupus Erythematosus.

Internal medicine (Tokyo, Japan)
2026

Biomarker-stratified efficacy and safety of biologics in systemic lupus erythematosus: a systematic review and meta-analysis.

Lupus science &amp; medicine
2026

Atypical lupus nephritis unmasked after albumin correction: a diagnostic pitfall presenting with cerebral venous sinus thrombosis.

BMJ case reports
2025

Rethinking headache in juvenile systemic lupus erythematosus: the need for broader perspectives.

Arquivos de neuro-psiquiatria
2026

Precision immunotherapies for systemic lupus erythematosus: From pathogenic targets to translational horizons.

Autoimmunity reviews
2026

Glucagon-like peptide-1 receptor agonist and lupus nephritis in systemic lupus erythematosus with type 2 diabetes.

The American journal of medicine
2026

The role of clot waveform analysis and related parameters in the diagnosis and treatment of systemic lupus erythematosus.

Thrombosis research
2026

CD39 Expression in Peripheral CD4+ T Lymphocytes Is Associated With Disease Activity in Patients With Systemic Lupus Erythematosus.

Journal of immunology research
2026

Barriers to therapy adherence in a group of Italian patients with systemic lupus erythematosus.

Clinical and experimental rheumatology
2026

Association between autoimmune diseases and the gut microbiome.

International immunology
2026

Remodeling the Inflammatory Microenvironment: Nanomaterial-Based Targeted Strategies for Systemic Lupus Erythematosus and Lupus Nephritis.

Small science
2026

Atopic Comorbidities Associated With Chronic Spontaneous Urticaria: A Case-Control Analysis of the All of Us Research Program.

JEADV clinical practice
2026

Ischemic duodenal injury due to systemic lupus erythematosus: A case report.

World journal of gastroenterology
2026

Clinical significance of miR-146a-5p and miR-192-5p expression in relation to disease activity and immunobiochemical markers in systemic lupus erythematosus.

Molecular biology reports
2026

Psychosis in patients with systematic lupus erythematosus: A systematic literature review and meta-analysis.

Lupus
2026

Cognitive Screening and Neuropsychological Evaluation in Children and Young Adults With Childhood-Onset Systemic Lupus Erythematosus: A Survey of Rheumatologists.

ACR open rheumatology
2026

Clinical and Immunological Profiles With Treatment Patterns in Systemic Lupus Erythematosus Patients in the Eastern Part of India: A Retrospective, Hospital-Based, Cross-Sectional Study.

Cureus
2026

Natural killer cells as biomarkers for disease activity, lupus nephritis, and time to remission in treatment-naïve childhood-onset systemic lupus erythematosus: a cohort study.

Pediatric rheumatology online journal
2026

Risk Factors for Peritonitis in Patients With Systemic Lupus Erythematosus Undergoing Peritoneal Dialysis.

International journal of rheumatic diseases
2026

Exploring the metabolic mysteries: Mechanistic insights into lactylation-mediated regulation of autoimmune diseases.

Autoimmunity reviews
2026

Influence of frailty syndrome on disease outcomes in systemic lupus erythematosus: a systematic review and narrative synthesis.

Current medical research and opinion
2026

Models Integrating Disease Heterogeneity and MPA Exposure Predict Systemic and Renal Efficacy of Mycophenolate in Pediatric Lupus Nephritis.

Pharmacotherapy
2026

Validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) in a Chinese Cohort: Comparison with SLEDAI-2-K.

Rheumatology and therapy
2026

Memory-biased CD8αα⁺ T cells show reduced abundance and phenotypic remodeling in SLE.

Immunologic research
2026

Integrating Patient-Reported Quality Measures in SLE: Development of the American College of Rheumatology Implementation Guide.

Arthritis care &amp; research
2026

Developing and Evaluating a Laboratory-Based Frailty Index (FI-Lab) for the Prediction of Long-Term Health Outcomes in Systemic Lupus Erythematosus.

Arthritis care &amp; research
2026

Clinical Significance of Therapeutic Drug Level Monitoring for Mycophenolate in Patients with Extra-Renal Systemic Lupus Erythematosus - A Systematic Review & Meta-analysis.

Arthritis care &amp; research
2026

Unveiling Endotypes in Systemic Lupus Erythematosus Through Multi-Omic Analysis: Insights into Cardiovascular and Renal Complications.

Arthritis &amp; rheumatology (Hoboken, N.J.)
2026

Serum Endocan in Systemic Lupus Erythematosus: Implication for Endothelial Dysfunction and Cardiovascular Risk.

International journal of rheumatic diseases
2026

The Th17/Treg axis: a key to understanding and treating autoimmune disorders.

Open life sciences
2026

Apolipoprotein L1 High-Risk Genotypes are Associated With Lupus Nephritis Incidence.

Kidney international reports
2026

Exosomal non-coding RNAs in autoimmune diseases: molecular mechanisms and potential applications.

Frontiers in immunology
2026

Non-Conventional and Emerging Autoantibodies in Sjögren's Disease.

Journal of inflammation research
2026

Cardiac Complications in Systemic Lupus Erythematosus: A Systematic Review of Diagnostic and Prognostic Gaps.

Cureus
2026

Purulent Pericarditis With Cardiac Tamponade Triggered by Left-Sided Infective Endocarditis in Active Systemic Lupus Erythematosus: A Case Report.

Cureus
2026

Risk factors for depression in systemic lupus erythematosus: a systematic review and meta-analysis.

Frontiers in medicine
2026

From Hemolysis to Lupus: A Case of Evans Syndrome Revealing Systemic Autoimmunity.

Clinical case reports
2026

Bioinformatics Analysis Reveals ALDH5A1: A Novel Molecular Brake on Th17 Cell Pathogenicity in Systemic Lupus Erythematosus.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2026

Vagus nerve stimulation in autoimmune diseases: Mechanisms, therapeutic potential, and clinical applications.

Autoimmunity reviews
2026

Erythroderma-Like Manifestations and High Fever in Palisaded Neutrophilic and Granulomatous Dermatitis Without Any Underlying Systemic Immunological Disease.

The Journal of dermatology
2026

ShenQi DiHuang Decoction (SQDHD) Ameliorates Neuroinflammation and Neuropsychiatric Manifestations in Pristane Induced Lupus Mice via Blocking JAK1-STAT3 Pathway.

CNS neuroscience &amp; therapeutics
2026

Endothelial Dysfunction: Insights into Systemic Lupus Erythematosus-associated Cardiovascular Disease and Neuropsychiatric Manifestations.

Journal of cardiovascular translational research
2026

CAR-T therapy for autoimmune rheumatic diseases: navigating clinical frontiers between breakthroughs and uncertainties.

Clinical and experimental medicine
2026

Clinical Characteristics of 30 Cases of Childhood Haemolytic Uremic Syndrome in a Single Centre.

Nephrology (Carlton, Vic.)
2026

Association of Mitochondrial DNA Genetic Variants With Depression and Anxiety in Chinese Patients With Systemic Lupus Erythematosus.

International journal of rheumatic diseases
2026

Progression from at-risk state to clinical and severe systemic lupus erythematosus involves molecular dysregulations potentially reversible by biologics: implications for early diagnosis and treatment.

Annals of the rheumatic diseases
2026

Clinical utility and performance of anti-C1q antibodies for SLE: comparative analysis of three different assays.

Lupus science &amp; medicine
2026

LGALS3BP promotes M1 polarization of macrophages and interacts with LGALS3, damaging endothelial function and exacerbating pulmonary arterial hypertension in systemic lupus erythematosus.

Pathology, research and practice
2026

Neutralizing autoantibodies against interferon alpha in systemic lupus erythematosus: Prevalence, age of onset, and clinical associations.

Lupus
2026

'Water Target Sign' on CT Scan in Systemic Lupus Erythematosus: Correspondence.

Indian journal of pediatrics
Ver todos os 38.990 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Lúpus eritematoso sistêmico.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Lúpus eritematoso sistêmico

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Magnetic Resonance Imaging-Negative Lupus Myelitis: A Narrative Review.
    Annals of Indian Academy of Neurology· 2026· PMID 41876405mais citado
  2. Long-term outcomes of hydroxychloroquine dose reduction in Puerto Ricans with systemic lupus erythematosus: 6-year follow-up.
    Lupus science &amp; medicine· 2026· PMID 41876094mais citado
  3. 'Getting comfortable with the uncomfortable': barriers, facilitators and influences on reproductive health discussions from Hispanic women with systemic lupus erythematosus in the USA - a qualitative study.
    Lupus science &amp; medicine· 2026· PMID 41876093mais citado
  4. Clinical, laboratory, and histopathological characteristics of pediatric lupus nephritis: a retrospective study in a national referral center in Mexico.
    Frontiers in pediatrics· 2026· PMID 41867940mais citado
  5. Advances in endoplasmic reticulum stress response in immune-associated skin diseases: Mini-review.
    Tissue &amp; cell· 2026· PMID 41864071mais citado
  6. Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis: A Systematic Review and Meta-Analysis.
    Rheumatol Ther· 2026· PMID 41995998recente
  7. Unusual Presentation of Pustular Psoriasis on the Face: A Case Report.
    Cureus· 2026· PMID 41994815recente
  8. Contraception in Women With Medical Comorbidities: Clinical Risk Stratification and Individualized Therapeutic Strategies.
    Cureus· 2026· PMID 41994729recente
  9. Effusive-constrictive pericarditis in a patient with late-onset systemic lupus erythematosus.
    J Cardiol Cases· 2026· PMID 41994075recente
  10. Serum RNASE1 as a biomarker for disease activity and lupus nephritis in systemic lupus erythematosus.
    Front Immunol· 2026· PMID 41993198recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:536(Orphanet)
  2. OMIM OMIM:152700(OMIM)
  3. MONDO:0007915(MONDO)
  4. Lupus Eritematoso Sistemico(PCDT · Ministério da Saúde)
  5. GARD:18695(GARD (NIH))
  6. Variantes catalogadas(ClinVar)
  7. Busca completa no PubMed(PubMed)
  8. Artigo Wikipedia(Wikipedia)
  9. Q1485(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Lúpus eritematoso sistêmico
Compêndio · Raras BR

Lúpus eritematoso sistêmico

ORPHA:536 · MONDO:0007915
🇧🇷 Brasil SUS
CEAF
1BAzatioprina
Geral
Prevalência
1-5 / 10 000
Herança
Not applicable
CID-10
M32.0 · Lúpus eritematoso disseminado [sistêmico] induzido por drogas
CID-11
Ensaios
40 ativos
Início
Adolescent, Adult, Childhood, Infancy
Prevalência
47.0 (France)
MedGen
UMLS
C0024141
Repurposing
3 candidatos
dexamethasoneglucocorticoid receptor agonist
dexamethasone-acetate
prednisolone-sodium-phosphate
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades